DELFI Diagnostics to Present First Clinical Utility Data for Blood-Based Lung Cancer Screening at ATS 2026
DELFI Diagnostics is set to present five abstracts at the ATS 2026 International Conference, showcasing the first clinical utility data for a blood-based lung cancer screening test, FirstLook™ Lung. The cornerstone of their presentation is the L301 FIRSTLUNG study, which evaluates whether offering blood-based testing increases lung cancer screening rates. Current low screening rates for lung cancer in the U.S. underscore the importance of this test, which is designed to integrate with routine blood work and reach underserved populations.
Late-breaking oral presentation of the L301 FIRSTLUNG Study highlights first-of-its-kind evidence that a blood-based test can increase lung cancer screening uptake; five total presentations span clinical utility, real-world implementation, and health equity across three health systems…